NCT07408869撤回1 期
A Phase 1b, Open-Label Study Evaluating the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Cizutamig in IgE Mediated Diseases
Candid Therapeutics1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年4月1日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- To evaluate the ability of cizutamig to reduce IgE levels
研究概览
简要总结
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
详细描述
This is a Phase 1b, open-label study evaluating the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient meets at least one of the following:
- •History of documented (skin prick test, in vitro testing, or food challenge), ongoing, IgE-mediated allergy to food (eg, peanut, hazelnut, walnut, cashew, milk, egg/egg white, soy, wheat, sesame, cod, salmon, tuna, lobster, crab and/or shrimp) with Screening total IgE ≥ 400 IU/mL
- •Diagnosis of chronic rhinosinusitis with Screening total IgE > ULN
- •Diagnosis of allergic rhinitis with Screening total IgE > ULN
- •Diagnosis of asthma and classified as well controlled per 2024 Global Initiative for Asthma guidelines with Screening total IgE > ULN
- •Diagnosis of chronic spontaneous urticaria with symptoms (eg, wheals or angioedema) for at least 6 weeks any time prior to screening and Screening total IgE > ULN
- •Diagnosis of atopic dermatitis that has been present for at least 6 months before the screening visit and with Screening total IgE > ULN
- •Agree to the use of highly effective contraception
排除标准
- •Elevated IgE levels for reasons other than the IgE mediated diseases
- •Planned ingestion of food items to which they are allergic for the duration of the study (for food allergy patients)
- •Current use of any allergen immunotherapy.
- •Individuals whose allergen exposures in their home and/or work environments may be expected to change significantly during the trial period
- •Inadequate clinical laboratory parameters at Screening
- •Receipt of or inability to discontinue any excluded therapies
- •Individuals who will decline blood products
- •Active infection
- •Serious mental illness, drug or alcohol abuse, dementia, or other condition that impair ability to sign ICF
- •Individuals who are hypersensitive to intravenous immunoglobulin (IVIg)
- •History of primary immunodeficiency
- •History of CNS disease
- •History of poorly controlled diabetes, chronic kidney disease, chronic pulmonary disease, uncontrolled cardiovascular disease, history of malignancy within 5 years
- •History of severe allergic or anaphylactic reactions to mAb therapy (or recombination antibody-related fusion proteins) or any constituents of study drug
- •Major surgery requiring the use of general anesthesia within 12 weeks prior to Screening or planned or expected major surgery during the study period
- •Blood donation or significant blood loss within 30 days prior to screening
- •Individuals considered to be part of a vulnerable population (eg, incarceration)
- •Individuals that in the opinion of the Investigator, are not suitable for participation in the trial
- •Inability to comply with protocol-mandated requirements
- •A history of severe allergic or anaphylactic reactions related to the underlying IgE mediated disease
研究组 & 干预措施
cizutamig (multiple dose)
Experimental
cizutamig will be dosed subcutaneously according to the cohort assignment
干预措施: Cizutamig (Biological)
cizutamig (single dose)
Experimental
cizutamig will be dosed subcutaneously according to the cohort assignment
干预措施: Cizutamig (Biological)
结局指标
主要结局
To evaluate the ability of cizutamig to reduce IgE levels
时间窗: Baseline to Week 12
Change from baseline in serum IgE
次要结局
- Incidence and severity of treatment-emergent adverse events through end of study(Baseline to Week 24)
- PK parameters: Cmax(Baseline to 24 Weeks)
- PK parameters: Tmax(Baseline to Week 24)
- PK parameters: AUC(Baseline to 24 Weeks)
- PK Parameter: CL(Baseline to 24 Weeks)
- PK Parameters: Vd(Baseline to 24 Weeks)
- PK Parameters: t1/2(Baseline to 24 Weeks)
- Anti-drug antibodies (ADAs)(Baseline to 24 Weeks)
- Changes in body temperature(Baseline to 24 Weeks)
- Changes to blood pressure(Baseline to 24 Weeks)
- Changes in heart rate(Baseline to 24 Weeks)
- Changes to respiratory rate(Baseline to 24 Weeks)
- Changes to pulse oximetry(Baseline to 24 Weeks)
- Changes in ECG parameters: QRS interval(Baseline to 24 Weeks)
- Changes in ECG parameters: PR interval(Baseline to 24 Weeks)
- Changes in ECG parameters: QTcB(Baseline to 24 Weeks)
- Changes in ECG parameters: QTcF(Baseline to 24 Weeks)
- Changes in ECG parameters: QT interval(Baseline to 24 Weeks)
- Changes in ECG parameters: RR(Baseline to 24 Weeks)
- Changes from baseline in safety laboratory assessments through end of study: serum chemistry(Baseline to 24 Weeks)
- Changes from baseline in Red Blood Cell count(Baseline to 24 Weeks)
- Changes from baseline in White Blood Cell count(Baseline to 24 Weeks)
- Changes from baseline in Platelets(Baseline to 24 Weeks)
- Changes from baseline in Hematocrit(Baseline to 24 Weeks)
- Changes from baseline in Hemoglobin(Baseline to 24 Weeks)
- Frequency and percentage of anti-drug antibodies (ADAs)(Baseline to 24 Weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)2024-513708-33-00Sutro Biopharma Inc.20
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe DiseaseNCT07354724Denali Therapeutics Inc.32
招募中
2 期
Clinical trial of MDNA11 (investigational drug) administered alone or in combination with pembrolizumab (immune checkpoint inhibitor) in Patients with Advanced Solid Tumors2023-507536-21-00Medicenna Therapeutics Inc.50
招募中
2 期
A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII DeficiencyNCT07347249Hemab ApS18
招募中
1 期
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid TumorsNCT07328217Dizal Pharmaceuticals203